Karyopharm Therapeutics Stock Forward View - Simple Moving Average
| KPTI Stock | USD 6.52 0.11 1.66% |
Karyopharm Stock outlook is based on your current time horizon. We recommend always using this module together with an analysis of Karyopharm Therapeutics' historical fundamentals, such as revenue growth or operating cash flow patterns.
As of 1st of February 2026, the RSI of Karyopharm Therapeutics' share price is approaching 48. This indicates that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Karyopharm Therapeutics, making its price go up or down. Momentum 48
Impartial
Oversold | Overbought |
Using Karyopharm Therapeutics hype-based prediction, you can estimate the value of Karyopharm Therapeutics from the perspective of Karyopharm Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Simple Moving Average forecasted value of Karyopharm Therapeutics on the next trading day is expected to be 6.52 with a mean absolute deviation of 0.29 and the sum of the absolute errors of 17.08. Karyopharm Therapeutics after-hype prediction price | USD 6.47 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Karyopharm | Build AI portfolio with Karyopharm Stock |
Karyopharm Therapeutics Additional Predictive Modules
Most predictive techniques to examine Karyopharm price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Karyopharm using various technical indicators. When you analyze Karyopharm charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Karyopharm Therapeutics Simple Moving Average Price Forecast For the 2nd of February
Given 90 days horizon, the Simple Moving Average forecasted value of Karyopharm Therapeutics on the next trading day is expected to be 6.52 with a mean absolute deviation of 0.29, mean absolute percentage error of 0.13, and the sum of the absolute errors of 17.08.Please note that although there have been many attempts to predict Karyopharm Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Karyopharm Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Karyopharm Therapeutics Stock Forecast Pattern
| Backtest Karyopharm Therapeutics | Karyopharm Therapeutics Price Prediction | Buy or Sell Advice |
Karyopharm Therapeutics Forecasted Value
In the context of forecasting Karyopharm Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Karyopharm Therapeutics' downside and upside margins for the forecasting period are 2.01 and 11.03, respectively. We have considered Karyopharm Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Moving Average forecasting method's relative quality and the estimations of the prediction error of Karyopharm Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Karyopharm Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 112.4319 |
| Bias | Arithmetic mean of the errors | -0.027 |
| MAD | Mean absolute deviation | 0.2894 |
| MAPE | Mean absolute percentage error | 0.044 |
| SAE | Sum of the absolute errors | 17.075 |
Predictive Modules for Karyopharm Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Karyopharm Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Karyopharm Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Karyopharm Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Karyopharm Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Karyopharm Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Karyopharm Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Karyopharm Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Karyopharm Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Karyopharm Therapeutics' historical news coverage. Karyopharm Therapeutics' after-hype downside and upside margins for the prediction period are 1.96 and 10.98, respectively. We have considered Karyopharm Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Karyopharm Therapeutics is slightly risky at this time. Analysis and calculation of next after-hype price of Karyopharm Therapeutics is based on 3 months time horizon.
Karyopharm Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Karyopharm Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Karyopharm Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Karyopharm Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.22 | 4.51 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | Uncertain |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
6.52 | 6.47 | 0.77 |
|
Karyopharm Therapeutics Hype Timeline
Karyopharm Therapeutics is now traded for 6.52. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Karyopharm is anticipated to decline in value after the next headline, with the price expected to drop to 6.47. The average volatility of media hype impact on the company price is insignificant. The price decrease on the next news is expected to be -0.77%, whereas the daily expected return is now at 0.22%. The volatility of related hype on Karyopharm Therapeutics is about 0.0%, with the expected price after the next announcement by competition of 6.52. About 31.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 14.7. Karyopharm Therapeutics had not issued any dividends in recent years. The entity had 1:15 split on the 26th of February 2025. Given the investment horizon of 90 days the next anticipated press release will be uncertain. Check out Historical Fundamental Analysis of Karyopharm Therapeutics to cross-verify your projections.Karyopharm Therapeutics Related Hype Analysis
Having access to credible news sources related to Karyopharm Therapeutics' direct competition is more important than ever and may enhance your ability to predict Karyopharm Therapeutics' future price movements. Getting to know how Karyopharm Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Karyopharm Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| SNTI | Senti Biosciences | 0.00 | 0 per month | 0.00 | (0.12) | 7.73 | (9.50) | 53.50 | |
| BRNS | Barinthus Biotherapeutics plc | 0.00 | 0 per month | 0.00 | (0.17) | 5.71 | (7.79) | 24.01 | |
| CVM | CEL SCI Corp | 0.00 | 0 per month | 0.00 | (0.03) | 10.19 | (9.54) | 30.91 | |
| XFOR | X4 Pharmaceuticals | 0.00 | 0 per month | 0.00 | (0.02) | 7.28 | (5.21) | 23.09 | |
| ALGS | Aligos Therapeutics | 0.00 | 0 per month | 5.07 | 0.04 | 10.16 | (7.89) | 28.43 | |
| FGEN | FibroGen | 0.00 | 0 per month | 0.00 | (0.07) | 4.33 | (8.15) | 28.75 | |
| INMB | INmune Bio | 0.00 | 0 per month | 0.00 | (0.04) | 6.82 | (7.91) | 22.66 | |
| MRSN | Mersana Therapeutics | 0.00 | 0 per month | 1.32 | 0.15 | 3.68 | (1.36) | 210.61 | |
| MDCX | Medicus Pharma Ltd | 0.00 | 0 per month | 0.00 | (0.22) | 6.22 | (8.93) | 21.20 | |
| TELO | Telomir Pharmaceuticals Common | 0.00 | 0 per month | 0.00 | (0.13) | 3.85 | (6.00) | 17.75 |
Other Forecasting Options for Karyopharm Therapeutics
For every potential investor in Karyopharm, whether a beginner or expert, Karyopharm Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Karyopharm Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Karyopharm. Basic forecasting techniques help filter out the noise by identifying Karyopharm Therapeutics' price trends.Karyopharm Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Karyopharm Therapeutics stock to make a market-neutral strategy. Peer analysis of Karyopharm Therapeutics could also be used in its relative valuation, which is a method of valuing Karyopharm Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Karyopharm Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Karyopharm Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Karyopharm Therapeutics shares will generate the highest return on investment. By undertsting and applying Karyopharm Therapeutics stock market strength indicators, traders can identify Karyopharm Therapeutics entry and exit signals to maximize returns.
Karyopharm Therapeutics Risk Indicators
The analysis of Karyopharm Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Karyopharm Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting karyopharm stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 3.68 | |||
| Semi Deviation | 4.18 | |||
| Standard Deviation | 4.51 | |||
| Variance | 20.37 | |||
| Downside Variance | 18.88 | |||
| Semi Variance | 17.44 | |||
| Expected Short fall | (4.02) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Karyopharm Therapeutics
The number of cover stories for Karyopharm Therapeutics depends on current market conditions and Karyopharm Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Karyopharm Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Karyopharm Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Karyopharm Therapeutics Short Properties
Karyopharm Therapeutics' future price predictability will typically decrease when Karyopharm Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Karyopharm Therapeutics often depends not only on the future outlook of the potential Karyopharm Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Karyopharm Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 8.1 M | |
| Cash And Short Term Investments | 108.7 M |
Check out Historical Fundamental Analysis of Karyopharm Therapeutics to cross-verify your projections. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is there potential for Biotechnology market expansion? Will Karyopharm introduce new products? Factors like these will boost the valuation of Karyopharm Therapeutics. Expected growth trajectory for Karyopharm significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Karyopharm Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Karyopharm Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Karyopharm Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.